Another Brick in the Wall: The FDA Releases Draft Clinical Pharmacology Guideline for Biosimilar Development

Posted on

AAPS Blog

By Robert G. Bell

Robert Bell

In May, the FDA released its new draft guidance Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference Product. The draft guidance addresses pharmacokinetic (PK) and pharmacodynamic (PD) comparisons of biosimilars to reference biologic products required as part of a stepwise approach to developing the data and information (totality of evidence) necessary to support biosimilarity. The clinical pharmacology assessment may be an important component of the scientific justification supporting extrapolation of clinical data to one or more additional conditions of use.

View original post 311 more words

Advertisements

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s